Oncology / Haematology

A RANDOMIZED PHASE III STUDY OF DURATION OF ANTI-PD-1 THERAPY IN METASTATIC MELANOMA

Trial Name:  STOP-GAP  PI:  Dr Oliver Klein

 

Who can take part:

  • Histologically confirmed melanoma that is unresectable / metastatic (stage III or stage IV).
  • Patients must have evidence of unresectable / metastatic disease, that is considered evaluable by the investigator and can be followed, but measurable disease is not mandatory
  • Patients with brain metastases are allowed, provided they are stable

Exclusion criteria:

  • Patients not willing to stop anti-PD-1 therapy, if randomized to the intermittent arm.

For further information please contact Ellen – 9784-8562

Trial Phase

Non-drug Phase 1 Phase 2 Phase 3 Phase 4